ArticleBMC oral health2026
Salvianolic acid B functionalized injectable GelMA hydrogel for pulpitis in a vital pulp therapy: a dual anti-inflammatory property and enhanced reparative dentinogenesis activity material.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Salvianolic Acid B Attenuates Excitotoxic Neuronal Injury After Transient Cerebral Ischemia.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundVital pulp therapy (VPT) is recognized as a minimally invasive alternative to root canal treatment for teeth with initial and mild to moderate pulpitis. However, effective inflammation control remains a key challenge, as existing pulp capping materials exhibit limited anti-inflammatory efficacy. This study aimed to develop an injectable, photocurable pulp capping material with dual anti-inflammatory and pro-odontogenic functions to improve VPT outcomes for inflamed pulp.
methodsThe Sal B/GelMA composite hydrogel was synthesized and characterized for physicochemical properties, drug release profile, and biodegradation. Its cytocompatibility was assessed using CCK-8 assay, live/dead staining, and cytoskeletal (F-actin) observation. The migration of human dental pulp stem cells (hDPSCs) was evaluated via a wound healing assay. In vitro, hDPSCs were cultured with lipopolysaccharide (LPS) to mimic an inflammatory environment. The anti-inflammatory effect of Sal B/GelMA hydrogel was evaluated by measuring the mRNA levels of IL-1β, IL-6, and TNF-ɑ. Odontogenic differentiation was assessed by alkaline phosphatase (ALP) activity, alizarin red S staining, and the expression of Runx2, OCN, DMP1, and DSPP. A rat pulpitis model was established for in vivo evaluation. The hydrogel’s ability to alleviate inflammation and stimulate reparative dentin formation was evaluated using micro-CT, hematoxylin and eosin (H&E) staining, Masson’s trichrome staining, and immunohistochemistry.
resultsThe hydrogel exhibited a porous microstructure, excellent cytocompatibility, biodegradability, and sustained Sal B release kinetics. In LPS-induced hDPSCs, it significantly suppressed pro-inflammatory cytokine expression while concurrently enhancing odontogenic differentiation, as evidenced by upregulated gene expression, increased ALP activity, and enhanced mineralization. In vivo, the Sal B/GelMA hydrogel exhibited favorable biocompatibility with no signs of obvious tissue necrosis at the implantation site. Moreover, it effectively reduced early inflammatory infiltration and induced substantial reparative dentin formation with superior structural homogeneity compared to iRoot BP Plus.
conclusionsThe Sal B/GelMA hydrogel possesses dual anti-inflammatory and pro-odontogenic functionalities, suggesting its potential as a promising bioactive pulp capping material to enhance inflamed pulp repair and improve VPT outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.